Induced Pluripotent Stem Cells News and Research

RSS

Study on Helicos BioSciences' single molecule sequencing technology published

Helicos BioSciences Corporation today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid.

4 Dec 2009

Vitro Diagnostics files a patent application for its technology related to generation of iPS cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the filing of a new United States patent application entitled “POU5-F1 Expression in Human Mesenchymal Stem Cells” and the development of new technology related to generation of human induced pluripotent stem cells (iPS).

2 Dec 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

Scientists identify molecular disparity between iPS cells and embryonic stem cells

The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.

5 Nov 2009

GICD, Stanford University collaborate to develop stem cell and regenerative medicine therapies

Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) and Stanford University School of Medicine will collaborate in a new consortium funded by the National Heart, Lung and Blood Institute (NHLBI) to develop stem cell and regenerative medicine therapies. GICD investigators, led by GICD Director Deepak Srivastava, MD, will collaborate with a Stanford team led by Robert Robbins, MD, professor and chair of cardiothoracic surgery, to investigate how to use induced pluripotent stem cells, or iPS cells, to repair damaged heart muscle.

3 Nov 2009

Johns Hopkins bioethicists raise important issues on recent creation of live mice from iPSCs

The recent creation of live mice from induced pluripotent stem cells (iPSCs) not only represents a remarkable scientific achievement, but also raises important issues, according to bioethicists at The Johns Hopkins University's Berman Institute of Bioethics.

30 Oct 2009

NIGMS accelerates induced pluripotent stem cells study with Recovery Act funds

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health, is using $5.4 million of Recovery Act funds to accelerate basic studies of induced pluripotent stem cells. These cells, abbreviated iPS, are reprogrammed from skin or other easily obtained adult cells and appear to be similar to stem cells derived from embryos.

28 Oct 2009

New technique developed to transform regular body cells into artificial stem cells

Scientists have overcome a key barrier to the clinical use of stem cells with a technique which transforms regular body cells into artificial stem cells without the need for introducing foreign genetic materials, which could be potentially harmful. The research, published in STEM CELLS, suggests that cells taken from a patient's eye can be "reprogrammed" to replace or restore cells lost to degenerative diseases.

23 Oct 2009

NIH awards $8 million to The Medical College of Wisconsin for heart research

The Medical College of Wisconsin has been awarded a five-year, $8 million, multi-investigator Program Project Grant (PPG) from the National Institutes of Health to understand how human pluripotent stem cells, defined as cells which if left to their own designs can develop into any of the more than 200 cell types in the human body, can be channeled to exclusively become heart muscle cells.

22 Oct 2009

Study paves way for the creation of a stem cell library

The study, led by the University of Edinburgh's MRC Centre for Regenerative Medicine, paves the way for the creation of a stem cell library that can be used for in vitro hepatic disease models.

21 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

New maintenance medium for human embryonic and pluripotent stem cells

STEMCELL Technologies Inc. (STEMCELL) is pleased to announce the release of TeSR™2, a defined, animal-protein free maintenance medium for human embryonic and induced pluripotent stem cells. This medium takes a step towards addressing the needs of researchers working towards the culture of their cells in a medium free of animal-derived proteins.

15 Oct 2009

Human stem cells advance cancer vaccine research

Scientists from the United States and China have revealed the potential for human stem cells to provide a vaccination against colon cancer, reports a study published in STEM CELLS.

8 Oct 2009

IRSF awards $2M for research into a cure for Rett syndrome

The International Rett Syndrome Foundation (IRSF) announced today that it is awarding grants totaling $2 million to support 18 innovative research projects in 2009. Each project will explore bold new ideas that have the potential to drive the field forward and speed the translation of research into treatments and a cure for Rett syndrome.

3 Oct 2009

StemCells pushing forward its SC Proven cell culture product business

StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company’s ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company’s Cambridge, UK and Palo Alto, California locations.

23 Sep 2009

StemCells to take part in international networking event

StemCells, Inc. (NASDAQ:STEM) announced today its participation in the 2009 World Stem Cell Summit to be held September 21 – 23 in Baltimore, Maryland.

22 Sep 2009

Research reveals that iPSCs similar to embryonic stem cells

A team of researchers from the University of California, San Diego School of Medicine and the Salk Institute for Biological Studies in La Jolla have developed a safe strategy for reprogramming cells to a pluripotent state without use of viral vectors or genomic insertions. Their studies reveal that these induced pluripotent stem cells (iPSCs) are very similar to human embryonic stem cells, yet maintain a "transcriptional signature." In essence, these cells retain some memory of the donor cells they once were.

18 Sep 2009

Stem cells - the answer to autoimmune diseases and cancer in the future

Stem cells are multipotent cells of the immune system. Scientists hope to use them for curing autoimmune diseases, cancer and innate genetic defects in the future.

16 Sep 2009

Researchers use mTeSR1 medium for deriving human induced pluripotent stem cells

In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR™1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.

15 Sep 2009